novo nordisk glp-1 receptor agonists weight management diabetes treatments In the original clinical trials looking at semaglutide (the in Nordisk's Ozempic and Wegovy) and tirzepatide (in Eli Lilly's Mounjaro and Zepbound), patients gained back most of the after GLP-1 Agonists For Obesity In
Description
doi: 10.1016/j.molmet.2019.09.010
GLP-1 agonists suppress TGF-/Smad signalling, reducing collagen deposition and myocardial stiffness [80]
Fontana, Genve (Angiologie)
A degree of statistical heterogeneity, as measured by the I 2 statistic, was present in the analyses for change in HbA 1c and body weight
Real-world data on effectiveness and safety may differ from findings in controlled studies, highlighting the need for additional larger-scale studies and real-world data to guide clinical decision-making
